Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hillmar I and Zöllner N | Saturated and unsaturated 1-0-alkyl-2-0-acetoyl-sn-glycero-3-phosphocholines and 2-lyso derivatives from ratfish liver oil. Effect on adenosine 3':5'-cyclic monophosphate concentration in hepatocyte suspensions. | 1983 | Res Exp Med (Berl) | pmid:6310713 |
| Mauco G et al. | Platelet activating factor (PAF-acether) promotes an early degradation of phosphatidylinositol-4,5-biphosphate in rabbit platelets. | 1983 | FEBS Lett. | pmid:6311620 |
| Camussi G et al. | Release of platelet activating factor in rabbits with antibody-mediated injury of the lung: the role of leukocytes and of pulmonary endothelial cells. | 1983 | J. Immunol. | pmid:6311899 |
| Hwang SB et al. | Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes. | 1983 | Biochemistry | pmid:6313047 |
| Voelkel NF et al. | Platelet-activating factor causes pulmonary vasoconstriction and edema via platelet-independent leukotriene formation. | 1983 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:6221590 |
| Kloprogge E et al. | Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets. | 1983 | Thromb. Res. | pmid:6222507 |
| Hallam TJ et al. | The role of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AcGEPC) and palmitoyl-lysophosphatidate in the responses of human blood platelets to collagen and thrombin. | 1983 | FEBS Lett. | pmid:6617886 |
| Roussi J et al. | [Success of treatment with a low-molecular-weight heparin fraction in a case of pulmonary embolism complicated by heparin-induced thrombopenia]. | 1983 | Nouv Rev Fr Hematol | pmid:6622253 |
| Valone FH and Goetzl EJ | Enhancement of human polymorphonuclear leukocyte adherence by the phospholipid mediator 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC). | 1983 | Am. J. Pathol. | pmid:6624880 |
| Barradas MA et al. | The effect of fenfluramine on collagen-induced platelet aggregation in vitro. | 1983 | Br J Clin Pharmacol | pmid:6626443 |
| Benveniste J et al. | The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. | 1983 | Br. J. Pharmacol. | pmid:6652376 |
| Garcia Gil M and Sanchez Crespo M | Dansylcadaverine and rimantadine inhibition of phagocytosis, PAF-acether release, and phosphatidylcholine synthesis in human polymorphonuclear leukocytes. | 1983 | Immunopharmacology | pmid:6654649 |
| Tokumura A et al. | Biphasic action of platelet-activating factor on isolated guinea-pig ileum. | 1983 | Lipids | pmid:6656539 |
| Hamasaki Y et al. | [Effects of platelet activating factor (PAF:AGEPC) on airway and pulmonary vascular constriction of guinea pigs--with special reference to the relation with TXA2]. | 1983 | Kokyu To Junkan | pmid:6658209 |
| Björk J et al. | Paf-acether (platelet-activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds. | 1983 | Acta Physiol. Scand. | pmid:6659994 |
| McDonald TP and Kalmaz GD | Effects of thrombopoietin on the number and diameter of marrow megakaryocytes of mice. | 1983 | Exp. Hematol. | pmid:6832243 |
| Lewis JC et al. | Platelet-activating factor effects on pulmonary ultrastructure in rabbits. | 1983 | Exp. Mol. Pathol. | pmid:6832335 |
| Levy JV | Calmodulin antagonists inhibit aggregation of human, guniea pig and rabbit platelets induced with platelet activating factor. | 1983 | FEBS Lett. | pmid:6832368 |
| Touqui L et al. | Conversion of 3H-PAF acether by rabbit platelets is independent from aggregation: evidences for a novel metabolite. | 1983 | Biochem. Biophys. Res. Commun. | pmid:6838557 |
| Vermylen J et al. | Normal mechanisms of platelet function. | 1983 | Clin Haematol | pmid:6301715 |